Elekta: U.K.'s NHS Supply Chain Signs Agreement to Acquire 10 Elekta Linear Accelerator Systems for Cancer Treatment
Press release published at The Swedish Wire
CRAWLEY, England, June 18 - NHS Supply Chain (http://www.supplychain.nhs.uk/) will bring state-of-the-art cancer treatment to the United Kingdom by signing a deal to purchase ten Elekta Synergy® (http://www.elekta.com/healthcare-professionals/products/elekta-oncology/oncology-treatment-solutions/elekta-synergy.html) radiation therapy treatment systems. They will be delivered over the next 18 months. The deal begins to address the shortage of linear accelerators (linacs) in the U.K. and the replacement of aging linacs. According to the National Radiotherapy Advisory Group (NRAG), the NHS in England alone will need to replace a significant number of linacs between 2012 and 2016*. The order was booked during Elekta's fourth quarter 2011/12.
"NHS Supply Chain's selection of Elekta treatment solutions, as part of its efforts to improve cancer care in the United Kingdom, is a great honor," says Bill Yaeger, Executive Vice President, Elekta Oncology. "We hope to continue supporting its ongoing endeavors and are dedicated to being a valuable partner as NHS hospitals enhance their cancer management capabilities."
By acquiring the Elekta Synergy system, NHS Supply Chain will have the world's first linac to bring 3D and 4D image guidance into the treatment set-up process. The system is equipped with imaging tools that help clinicians visualize tumor targets and normal tissue, and their movement.
The integrated digital linac will allow NHS Supply Chain hospitals and clinics to evolve with the latest clinical advancements such as Volumetric Modulated Arc Therapy (VMAT) (http://www.elekta.com/healthcare-professionals/products/elekta-oncology/treatment-techniques/delivery-techniques/elekta-vmat.html) or a system upgrade with the Agility? (http://www.elekta.com/healthcare-professionals/products/elekta-oncology/treatment-techniques/beam-shaping/agility.html?utm_source=agility&utm_medium=redirect&utm_campaign=redirects)** beam-shaping device.
* Radiotherapy: developing a world class service for England (http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_074576.pdf)
**Agility is not licensed for sale in all markets. Please contact your local representative for details.
# # #
For further information, please contact:
Stina Thorman, Vice President Corporate Communications, Elekta AB
Tel: +46 8 587 254 37, email: firstname.lastname@example.org
Time zone: CET: Central European Time
Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: email@example.com
Time zone: ET: Eastern Time
Johan Andersson Melbi, Investor Relations Manager, Elekta AB
Tel: +46 702 100 451, email: firstname.lastname@example.org
Time zone: CET: Central European Time
The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07.30 CET on June 18, 2012.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,300 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.
This information was distributed by Cision